Sarepta shares fall 37% as FDA questions future of key gene therapy
Shares of Sarepta Therapeutics fell close to 37% on Friday after reports emerged that the US Food and Drug Administration...
Read moreShares of Sarepta Therapeutics fell close to 37% on Friday after reports emerged that the US Food and Drug Administration...
Read moreTalen Energy (NYSE: TLN) shares surged over 25% on Friday, reaching $330.99 in intraday trading and setting a new all-time...
Read moreThe UK’s national debt has quietly shrunk by millions of pounds after an unexpected move by a little-known government body.The...
Read moreAmazon Web Services (AWS), the cloud computing wing of Amazon, laid off several hundred employees on Thursday as part of...
Read moreJoby stock is on a tear this July, jumping 12% on Wednesday as it flirts with a new all-time high...
Read moreCanada is indicating a possible policy shift in one of its longest-running trade battles with the United States.British Columbia Premier...
Read moreAgainst the backdrop of rising global geopolitical tensions and growing economic uncertainty, the European Central Bank (ECB) is intensifying its...
Read moreUBS expects the US economy to slow significantly in 2025, projecting real GDP growth to fall to around 1%. In...
Read moreCoinbase Global is facing what analysts at Oppenheimer describe as an “unfavorable” setup heading into its second-quarter earnings report, with...
Read moreThe US Department of Defense (DoD) has awarded contracts to four major artificial intelligence developers. Alphabet Inc.’s Google, OpenAI, Anthropic...
Read more